Nabriva Therapeutics AG Probability of Future Stock Price Finishing Under 1.5
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
Nabriva |
Nabriva Therapeutics Target Price Odds to finish below 1.5
The tendency of Nabriva Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 1.50 or more in 90 days |
| 1.62 | 90 days | 1.50 | about 19.69 |
Based on a normal probability distribution, the odds of Nabriva Therapeutics to drop to $ 1.50 or more in 90 days from now is about 19.69 (This Nabriva Therapeutics AG probability density function shows the probability of Nabriva Stock to fall within a particular range of prices over 90 days) . Probability of Nabriva Therapeutics price to stay between $ 1.50 and its current price of $1.62 at the end of the 90-day period is about 46.57 .
Given the investment horizon of 90 days Nabriva Therapeutics AG has a beta of -0.23. This indicates as returns on the benchmark increase, returns on holding Nabriva Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Nabriva Therapeutics AG is likely to outperform the market. Additionally Nabriva Therapeutics AG has an alpha of 0.1426, implying that it can generate a 0.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Nabriva Therapeutics Price Density |
| Price |
Predictive Modules for Nabriva Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nabriva Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Nabriva Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nabriva Therapeutics is not an exception. The market had few large corrections towards the Nabriva Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nabriva Therapeutics AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nabriva Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | -0.23 | |
σ | Overall volatility | 0.09 | |
Ir | Information ratio | -0.001 |
Nabriva Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nabriva Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nabriva Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nabriva Therapeutics is not yet fully synchronised with the market data | |
| Nabriva Therapeutics may become a speculative penny stock | |
| Nabriva Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M). | |
| Nabriva Therapeutics AG currently holds about 20.04 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Nabriva Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nabriva Stock often depends not only on the future outlook of the current and potential Nabriva Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nabriva Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.7 M | |
| Cash And Short Term Investments | 12.4 M |
Nabriva Therapeutics Technical Analysis
Nabriva Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Nabriva Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nabriva Therapeutics AG. In general, you should focus on analyzing Nabriva Stock price patterns and their correlations with different microeconomic environments and drivers.
Nabriva Therapeutics Predictive Forecast Models
Nabriva Therapeutics' time-series forecasting models is one of many Nabriva Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nabriva Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Nabriva Therapeutics
Checking the ongoing alerts about Nabriva Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nabriva Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nabriva Therapeutics is not yet fully synchronised with the market data | |
| Nabriva Therapeutics may become a speculative penny stock | |
| Nabriva Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M). | |
| Nabriva Therapeutics AG currently holds about 20.04 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |